Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Nektar Therapeutics (NASDAQ:NKTR)

48.92
BATS BZX Real-Time Price
As of 1:49pm ET
 -1.06 / -2.12%
Today’s Change
11.41
Today|||52-Week Range
50.00
+298.70%
Year-to-Date
Company News For Nov 14, 2017
Nov 14 / Zacks.com - Paid Partner Content
Nektar (NKTR) Q3 Earnings & Sales Surpass, Sales View Up
Nov 08 / Zacks.com - Paid Partner Content
Nektar/Bristol-Myers' Combo Trial Positive in Phase I/II
Nov 13 / Zacks.com - Paid Partner Content
Nektar Therapeutics (NKTR) Jumps: Stock Rises 10.54%
Nov 08 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close49.98
Today’s open49.72
Day’s range47.71 - 49.89
Volume44,785
Average volume (3 months)1,696,689
Market cap$7.9B
Dividend yield--
Data as of 1:49pm ET, 11/22/2017

Growth & Valuation

Earnings growth (last year)-80.33%
Earnings growth (this year)+31.41%
Earnings growth (next 5 years)-7.38%
Revenue growth (last year)-28.32%
P/E ratioNM
Price/Sales10.35
Price/Book86.89

Competitors

 Today’s
change
Today’s
% change
AVXSAveXis Inc-0.09-0.09%
ONCESpark Therapeutics I...+2.19+3.01%
XONIntrexon Corp+1.10+8.89%
JUNOJuno Therapeutics In...+1.04+1.77%
Data as of 1:47pm ET, 11/22/2017

Financials

Next reporting dateFebruary 28, 2018
EPS forecast (this quarter)-$0.34
Annual revenue (last year)$165.4M
Annual profit (last year)-$153.5M
Net profit margin-92.80%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Howard W. Robin
Chief Operating Officer &
Senior Vice President
John Nicholson
Corporate headquarters
San Francisco, California

Forecasts